



PC1 / GB040700

GB04/4819



INVESTOR IN PEOPLE

The Patent Office

Concept House

Cardiff Road

Newport

South Wales

NP10 8QX

REC'D 07 JAN 2005

PCT

PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

R. McHenry
20 December 2004

BEST AVAILABLE COPY

17 NOV 2003 E852497-1 D02903
P01/7700 0.00-0326648.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

11160P1 GB/ED

2. Patent application number

(The Patent Office will fill this part in)

0326648.3

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

Reckitt Benckiser (UK) Limited

103-105 Bath Road

Slough

Berkshire

SL1 3UH

United Kingdom

UNIVERSITY OF SOUTHAMPTON

HIGHFIELD

SOUTHAMPTON

SO17 1BJ

Patents ADP number (*if you know it*)

00798470001

If the applicant is a corporate body, give the country/state of its incorporation

07972136002 ✓

England

4. Title of the invention

Method

5. Name of your agent (*if you have one*)

Elizabeth Anne DICKSON

c/o Reckitt Benckiser plc

Group Patents Department

Dansom Lane

Hull

HU8 7DS

United Kingdom

Patents ADP number (*if you know it*)

07517075002

7972136007

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
*(if you know it)*Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Yes

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description	15
Claim(s)	4
Abstract	1

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77) One

Request for a substantive examination (Patents Form 10/77) One

Any other documents (please specify) FS1

11. I/We request the grant of a patent on the basis of this application.

Signature(s)


Elizabeth Anne Dickson

Date 13 November 2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Elizabeth Anne Dickson 01482 582909

Elizabeth.Dickson@ReckittBenckiser.com

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

METHOD

The present invention relates to a method of deactivating dust mite allergens.

- 5 Various allergens are known to trigger a human reaction. For example, it has been known for a long time that house dust can trigger allergic reactions in humans, such as asthma and rhinitis. It was reported, as early as 1928 that it was the dust mites in the dust that were the primary source of the allergic response, but it was only in the 1960's that researchers appreciated its
10 significance.

House dust mites produce detritus which causes allergic reaction in many people. The major allergens are believed to be *Dermatophagoides farinae* (known as Der f1) and *Dermatophagoides pteronyssinus* (known as Der p1),
15 and to include faeces as well as body part residues of the house dust mites. A review is given in Experimental and Applied Acarology, 10 (1991) p. 167-186.

Other allergens which are problematic include cockroach allergens (notably the Bla g1 cockroach allergen). and cat allergens (Fel d1). In the case of cat
20 allergens the pelt of the cat and/or its salivary deposits seem to be of significance in eliciting the allergic response.

WO99/15208 describes a method for deactivating allergens derived from the D. Pteronyssinus and D. Farinae dust mite species, which comprises
25 contacting the allergen with one of 28 deactivants which are described. These are chemically diverse. They include cyclodextrin, urea, hydrogenated hop oil, aluminium chlorohydrate and silica gel.

WO01/76371 describes further deactivants for house dust mite allergens. The
30 further deactivants are cajeput oil (tea tree oil) and oils comprising one or more terpene hydrocarbons.

Clearly different types of compound may function as deactivants but there are still problems in finding deactivants which have high efficacy, and which are acceptable to consumers in a household environment. Firstly, most materials do not function as deactivants. Secondly, those that do often have an odour
5 which consumers find unacceptable. Many of the deactivants described in WO99/15208 and WO01/76371 have odours which consumers find too pungent and/or to have too pronounced a "sanitary" or "antiseptic" quality. Thirdly prior methods and/or deactivants have sometimes caused staining of surfaces to which they are applied.

10

In accordance with a first aspect of the present invention there is provided a method of deactivating an allergen, the method comprising dispersing into an airspace containing or able to support said allergen an allergen-deactivating amount of an allergen-deactivating compound (hereinafter "deactivant")
15 selected from one or more of the following compounds:

20

a citrus oil;
a mint oil;
bois de rose oil;
oil of jasmine;
frankincense;
oil of bergamot; and
oil of lemon grass.

25

Such compounds have pleasant scents yet are effective in combating allergens.

A preferred deactivant is a mint oil, most preferably spearmint oil.

30 A preferred deactivant is oil of jasmine.

A preferred deactivant is frankincense.

An especially preferred deactivant is a citrus oil, most preferably orange oil.

An especially preferred deactivant is bois de rose oil.

5

An especially preferred deactivant is oil of bergamot.

An especially preferred deactivant is oil of lemon grass.

10 A preferred method employs two or more of the deactivants defined in the first aspect of the invention, preferably dispersed into the airspace simultaneously; most preferably having been mixed prior to dispersal. This can give deactivant activity in excess of that which would be predicted from the activity of each deactivant tested separately.

15

An especially preferred method employs oil of bergamot and bois de rose oil. An admixture thereof represents a further aspect of the present invention.

20 An especially preferred method employs oil of lemon grass and bois de rose oil. An admixture thereof represents a further aspect of the present invention.

Another preferred method employs a citrus oil and oil of bergamot. An admixture thereof represents a further aspect of the present invention.

25 An especially preferred method employs a citrus oil and oil of jasmine. An admixture thereof represents a further aspect of the present invention.

Preferably the allergen combated by one of the oils defined above is a Der p1 and/or Der f1 allergen.

30

The deactivant may suitably be dispersed into the airspace over an extended period, for example at least 30 minutes, and preferably at least 1 hour.

The deactivant may suitably be dispersed into the airspace on two occasions, interrupted by a period in which there is no deactivant dispersal. Deactivant may be dispersed into the airspace on one or more further occasions, following

5 a corresponding period or periods of no deactivant dispersal. Preferably each such dispersal occasion involves deactivant dispersal over an extended period, as described above. Preferably the or each period in which there is no deactivant dispersal is an extended period, for example at least 2 hours, preferably at least 4 hours, and most preferably at least 8 hours. This

10 repeated dispersal method appears to be particularly valuable when the deactivant is a citrus oil.

There are various methods which can be used to disperse the deactivant into the airspace. Examples are discussed in the passages below. In these

15 passages the word deactivant is used to denote a single deactivant, and a plurality of deactivants used in a method of the invention, whether at the same time or at different times.

Preferably the deactivant is dispersed into the airspace as a vapour.

20

The deactivant may be vaporized by the use of heat. For example the deactivant, an oil, may be floated on water in an oil burner or heated directly in an oil burner. Alternatively the deactivant may be vaporized from a heated wick dipped into a reservoir of the deactivant.

25

Another method of dispersing the deactivant is by the ventilation of a source of the deactivant using an ion wind. An ion wind generates an ionized air flow which facilitates the evaporation and dispersal of the deactivant into the air. A unipolar charge is transferred to the molecules of the deactivant, which is

30 evaporated. Optionally the source of the deactivant may be heated in order to assist evaporation. The ion wind not only facilitates the evaporation and dispersal of the deactivant but also has the added advantage that the ion wind

generating device has no moving parts and thus operates at very low noise levels. The ion wind thus acts as an essentially silent fan. The charged molecules of the vaporized deactivant are attracted to particles in the air with an opposite or neutral charge and so may be more efficient at denaturing 5 airborne allergens than uncharged molecules. The charged molecules are also attracted to surfaces in the environment which is being treated and thus allergens on surfaces are also treated.

It will be understood that in order to obtain the desired level of the deactivant 10 evaporated into a room, the rate of evaporation of the deactivant will need to be taken into account, the surface area across which the deactivant is evaporated and the ion wind speed. Higher ion wind speeds will provide faster evaporation of the volatile components and thus the surface area across which the deactivant is evaporated will need to be adapted to the air flow speed.

15 The benefit of charging the molecules of the deactivant using an ion wind is two fold. The individual molecules are attracted as the allergen particles and, since all of the molecules have the same polarity charge, they are repelled one from another. Accordingly, the molecules tend to spread out to a great extent 20 as compared to uncharged molecules.

Allergen particles are normally electrically isolated from their surroundings and will typically be at a potential which is the same as that of their surroundings. An isolated allergenic particle within a cloud of electrically charged molecules 25 is likely to cause distortion of the electrical field so that the attraction of the charged molecules onto the allergen particle will be enhanced.

The deactivant may be used as such, or may be presented in the form of an emulsion. Generally, the emulsion will be an oil (i.e. deactivant)-in-water 30 emulsion comprising up to 5% by weight of the deactivant (in total, when more than one of said deactivants is employed). The formation of emulsions is generally well known in the art and is described, for example, in Modern

Aspects of Emulsion Science, edited by Bernard P. Binks, The Royal Society of Chemistry, 1998 and Surfactant Science and Technology, Second Edition, Drew Myers, 1992, VCH Publishers, Inc.

- 5 In a preferred aspect of the present invention a candle is used to promote the dispersal of the deactivant into the airspace. By the term "candle" as used herein is meant a solid, semi-solid or gelled body having a combustible body, which contains a wick which can carry a flame.
- 10 A candle may be located beneath a source of a deactivant, to accelerate its evaporation.

Alternatively or additionally the wick of a candle may deliver a deactivant by capillary action, from a source at one end of the candle, to be combusted at
15 the other end.

- Alternatively or additionally, and in any case preferably, a deactivant is incorporated into the combustible body of the candle.
- 20 A candle of use in the present invention preferably incorporates within its combustible body at least 2% by weight of the deactivant, preferably at least 5% by weight of the deactivant and more preferably at least 10% by weight of the deactivant (in total, when more than one of said deactivants is employed).
 - 25 Typically, the combustible body of the candle may be a blend of organic materials such as beeswax, paraffin wax, montan wax, carnauba wax, microcrystalline wax, fatty alcohols, fatty acids, fatty esters or natural and synthetic resins. Clear candles may comprise as the combustible material a gel comprising mineral oil containing blends of diblock and triblock copolymers
 - 30 based on synthetic thermoplastic rubbers or a gel obtained by combining a liquid base material of a hydrogenated polyolefin, a gelling agent and optionally a gel enhancing agent.

A wick normally extends longitudinally through the candle body. More than one wick may be used, if desired, but usually a single wick is centrally disposed in the candle body. When a candle wick is ignited, the wick is adapted to burn 5 gradually so that both the wick and the candle body are consumed.

Typically, the weight of candle which is burnt in a particular space to be treated will depend upon the actual volume of the space, e.g. room, to be treated.

10 The candle may suitably be burnt, and so its deactivant dispersed into the airspace, over an extended period, for example at least 1 hour, preferably at least 2 hours, and most preferably at least 5 hours.

15 The length of time for which the candle is burnt in the space to be treated will generally be for up to 2 hours, generally up to 5 hours, although in some circumstances the candle may be burnt for a longer period of time, such as 10 hours or more. However, it will be understood by those skilled in the art that an allergen denaturing effect will be obtained even if the candles containing the selected deactivants are burnt for a lesser period of time.

20 Another method of dispersing the deactivant is in the form of small droplets, preferably of mean diameter not exceeding 20 µm, preferably not exceeding 10 µm. Preferably such a method of dispersing small droplets is by use of an ultra-sonic jet nebuliser. The deactivant may be floated on the surface of water 25 in the nebuliser, or provided as an oil (i.e. deactivant)-in-water emulsion in the nebuliser. The nebuliser may suitably comprise a piezo-ceramic element which vibrates in the liquid (at 2-5 MHz). A plume of liquid may be generated by ultrasonic streaming. A dense cloud of very small droplets (most preferably of mean diameter <5µm) may then be expelled from the surface of the liquid.

30 A fan may be used to assist the expulsion of the nebulised droplets from the vessel.

The present invention involves the dispersal of an allergen deactivant into an airspace. It is possible that airborne allergens may be deactivated but it is believed that there is effective deactivation of allergens borne on surfaces within the airspace.

5

In accordance with a further aspect of the present invention there is provided the use in deactivating an allergen at a locus of one or more of the following materials:

- 10 a citrus oil;
- a mint oil;
- bois de rose oil;
- oil of jasmine;
- frankincense;
- 15 oil of bergamot;
- oil of lemon grass.

In accordance with a further aspect of the present invention there is provided use of one or more of the following materials:

- 20 a citrus oil;
- a mint oil;
- bois de rose oil;
- oil of jasmine;
- 25 frankincense;
- oil of bergamot;
- oil of lemon grass;

30 dispersed into an airspace in order to deactivate an allergen on a surface which is within that airspace. Preferably the dispersal is as a vapour.

Preferably an allergen deactivated in a method or use in accordance with the present invention is a material which evokes an allergic reaction in a human. For example it may be an allergen arising from house dust mites, or from pets. Most preferably the method or use of this invention is able to deactivate, 5 partially or wholly, an allergen arising from the mite species *Dermatophagoides farinae* (known as Der f1) or, especially from the mite species *Dermatophagoides pteronyssinus* (known as Der p1).

The present invention will be further described with reference to the following 10 Examples.

Experimental Protocol to Reduce Variability

When using house dust for allergen denaturing tests an inherent difficulty is the 15 variability of the amount of allergen in each small sample, even when taken from the same dust reservoir. The amount of dust in the pre-treatment sample must be accurately estimated in order to determine the extent of any allergen denaturing. In these tests the dust sample was applied to the test exposure surface and then one half of this surface dust was removed to measure the 20 control pre-treatment allergen level of that specific sample. Each control was directly relevant to each sample, which gave the best possible estimate of the level of allergen in the sample before exposure to possible denaturant. All tests employed a glass reinforced plastic booth of size 0.7m x 0.7m x 1.0m. All tests had 5 or 6 replicates. Average values are stated.

25 The following Examples all measure the reduction of the house dust mite *Dermatophagoides pteronyssinus* allergen - Der p1.

EXAMPLE 1 – hard surface / oil burner

30 House dust was passed through a number of sieves and the fraction smaller than 53 µm was collected. 0.025g of dust was placed in a small sieve to

- distribute it evenly over the test surface. The test surface was a PTFE (polytetrafluoroethylene – trade mark TEFLON) coated metal tray of size 30cm x 30cm. The dust was applied to the tray by moving the sieve continuously over the surface while tapping the sieve. One half of the dust was then
- 5 removed by suction onto an in-line filter and the weight recorded, this was the pre-treatment control. The tray was then placed in the booth. An oil burner containing 800µl of orange oil floated on 6ml of distilled water was placed in the booth, and the booth was sealed. The oil burner candle was lit and allowed to burn until all the liquid had been vaporised (approx. 30 minutes).
- 10 The candle was then smothered and the dust was left exposed in the booth. After 24 hours the tray was removed, the dust was collected from it and its weight recorded. The booth was washed with strong detergent between tests.

An identical test was carried out using water alone, with no orange oil.

- 15 The test samples were assayed for Der p1 using an ELISA (Enzyme linked immunosorbent assay) to determine the allergen content. This was then related to the weight of dust that had been present in each sample. All of the samples were multiplied up to compare the amount of allergen expected to be
- 20 present in a 0.1g sample of dust. The percentage difference between the control sample and the exposed sample was then obtained.

- The sample exposed to orange oil vapour showed a reduction in Der p1 allergen content of the test dust samples of 97.9%. The water-only sample
- 25 showed 23.8% reduction in allergen content.

EXAMPLE 2 – carpet / oil burner

- House dust was passed through a number of sieves and the fraction smaller
- 30 than 53 µm was collected. 0.1g of dust was placed in a small sieve to distribute it evenly over the test surface. The test surface was a 30cm² piece of polypropylene carpet. The dust was applied to the carpet by moving the

sieve continuously over the surface. One half of the dust was then removed by suction onto an in-line filter and the weight recorded, this was the pre-treatment control. The carpet was then placed in the booth.

- 5 For control tests dust was distributed on a like carpet piece, the pre-treatment control was exposed to water alone (6.8 ml) in the oil burner and the dust was left in the booth for 24 hours. The carpet was then removed, the dust was collected from the carpet and weighed. An oil burner containing 800 μ l of orange oil floated on 6ml of distilled water was placed in the booth, and the
10 booth was sealed. The oil burner candle was lit and allowed to burn until all the liquid had been vaporised (approx. 1 hour). The candle was then smothered and the dust was left exposed in the booth. After 16 hours the carpet was removed, the dust was collected from it and its weight recorded. The booth was washed with strong detergent between tests on the same
15 chemical.

The test samples were assayed for Der p1 using an ELISA (Enzyme linked immunosorbent assay) to determine the allergen content. This was then related to the weight of dust that had been present in each sample. All of the
20 samples were extrapolated up to compare the amount of allergen expected to be present in a 0.1g sample of dust. The percentage difference between the control sample and the exposed sample was then obtained.

Treatment using water alone gave Der p1 allergen reduction of 13.9%. The
25 orange oil gave a percentage reduction in the Der p1 allergen of 26.4%. When the test was repeated with a double dose of orange oil and water, together with water pre-treatment, the Der p1 allergen reduction was 94.6%.

EXAMPLE 3 - carpet / candle

30 Tests were carried out using candles loaded with deactivants. Test dust had been obtained from household vacuum cleaner bags. House dust was passed

through a number of sieves and the fraction smaller than 53 µm was collected. 0.1g of dust was placed in a small sieve to distribute it evenly over the test surface, a 30cm² piece of polypropylene carpet. The dust was applied by moving the sieve continuously over the surface. Dust was removed from half 5 of each test area by suction through an in-line glass fibre filter (2.5cm diameter) and the weight recorded. Test candles were prepared, each of approximately 100g before testing, with 2 wicks, and having a sterin:wax ratio of 2:10 (w/w) and 5% w/w of orange oil incorporated into the candle body, by a process of melting, mixing and setting. Candles were lit and placed in the 10 respective booths for 5 hours. A repeat operation was carried out 16 hours later with 6ml water pre-treatment. In some cases a further repeat operation was carried out after a further period of 16 hours. The candles were then smothered and the dust was left exposed in the rooms for 16 hours. The dust was then collected as for the controls and weighed. An unfragranced candle 15 was tested as a comparison.

During each 5 hour burn period approximately 27g of each candle tested was burnt. This equated to a rate of 270µl of deactivant released per hour.

20 The collected samples were assayed by Der p1 ELISA to determine the allergen content. This was then related to the weight of dust that had been present in each sample. All the samples were multiplied up to compare the amount of allergen expected to be present in a 0.1g sample of dust. The percentage differences between the control samples and the exposed samples 25 were then obtained.

Following 15 hours of burn time (3 x 5 hours) the unfragranced candle achieved a Der p1 allergen reduction of 36.3%. Following 10 hours of burn time (2 x 5 hours) the orange oil candle achieved a Der p1 allergen reduction 30 of 70.0%. Following 15 hours of burn time (3 x 5 hours) the orange oil candle achieved a Der p1 allergen reduction of 87.6%.

EXAMPLE 4 – hard surface / candle

Tests were carried out using candles loaded with deactivants. Test dust had been obtained from household vacuum cleaner bags. House dust was passed through a number of sieves and the fraction smaller than 53 µm was collected. 0.025g of dust was placed in a small sieve to distribute it evenly over the test surface, a 30cm x 30cm PTFE coated metal tray. The dust was applied by moving the sieve continuously over the surface. One half of the dust was then removed by suction onto an in-line filter and the weight recorded, this was the pre-treatment. The tray was then placed in the booth. Test candles were prepared, each of approximately 60g before testing, with two wicks, and having a sterin:wax ration of 2:10 (w/w) and 5% w/w of deactivant incorporated into the candle body, by a process of melting, mixing and setting. The deactivants were:

15

orange oil

spearmint oil

bois de rose oil

frankincense

20

oil of bergamot

oil of lemon grass

bois de rose oil and oil of bergamot (2.5% w/w each)

bois de rose oil and oil of lemon grass (2.5% w/w each).

25 Candles were lit and placed in respective booths for 5 hours. The candles were then smothered and the dust was left exposed in the booths for 16 hours. The dust was then collected as for the controls and weighed.

30 During the 5 hour burn period approximately 27g of each candle tested was burnt. This equated to a rate of 270µl of deactivant dispersed per hour.

The collected samples were assayed by Der p1 ELISA to determine the allergen content. This was then related to the weight of dust that had been present in each sample. All the samples were multiplied up to compare the amount of allergen expected to be present in a 0.1g sample of dust. The 5 percentage differences between the control samples and the exposed samples were then obtained.

The Der p1 allergen reductions were as follows:

- 10 orange oil – 67.8%
- spearmint oil – 37.7%
- bois de rose oil – 59.2%
- frankincense – 39.0%
- oil of bergamot – 44.7%
- 15 oil of lemon grass – 48.0%
- bois de rose oil and oil of bergamot (2.5% w/w each) – 79.1%
- bois de rose oil and oil of lemon grass (2.5% w/w each) – 61.5%.

EXAMPLE 5 – hard surface / candle

20 House dust was passed through a number of sieves and the fraction smaller than 53 µm was collected. 0.025g of dust was placed in a small sieve to distribute it evenly over the test surface. The test surface was a PTFE coated metal tray of size 30cm by 30cm. The dust was applied to the tray by moving 25 the sieve continuously over the surface while tapping the sieve. One half of the dust was then removed by suction onto an in-line filter and the weight recorded, this was the pre-treatment control. The tray was then placed in a booth. Candles were prepared, of approximately 60g before testing, with two wicks, and having a sterin:wax ratio of 2:10 (w/w) and 5% w/w of deactivant 30 incorporated into the candle body by a process of melting, mixing and setting. The deactivants were:

oil of bergamot and orange oil (2.5% w/w each)
oil of jasmine and orange oil (2.5% w/w each)
oil of jasmine (1% w/w) and orange oil (4% w/w)
oil of jasmine (4% w/w) and orange oil (1% w/w).

5

Candles were lit and placed in the booth for 5 hours. The candles were then smothered and the dust was left exposed in the booth for 16 hours. The dust was then collected as for the controls and weighed.

10 During the 5 hour burn period approximately 27g of each candle tested was burnt. This equated to a rate of 270 μ l of deactivant dispersed per hour.

15 The collected samples were assayed by Der p1 ELISA to determine the allergen content. This was then related to the weight of dust that had been present in each sample. All the samples were multiplied up to compare the amount of allergen expected to be present in a 0.1g sample of dust. The percentage differences between the control samples and the exposed samples were then obtained.

20 The Der p1 allergen reductions were as follows:

oil of bergamot and orange oil (2.5% w/w each) – 47.9%
oil of jasmine and orange oil (2.5% w/w each) – 75.1%
oil of jasmine (1% w/w) and orange oil (4% w/w) – 82.0%
25 oil of jasmine (4% w/w) and orange oil (1% w/w) – 82.0%.

CLAIMS:

1. A method of deactivating an allergen, the method comprising dispersing
5 into an airspace containing or able to support said allergen an allergen-
deactivating amount of an allergen-deactivating compound (hereinafter the
"deactivant") comprising one or more of the following compounds:

- a citrus oil;
10 a mint oil;
bois de rose oil;
oil of jasmine;
frankincense;
oil of bergamot; and
15 oil of lemon grass.

2. A method as claimed in claim 1, wherein the deactivant is dispersed into
the airspace over an extended period.

20 3. A method as claimed in claim 1 or 2, wherein the deactivant is dispersed
into the airspace as a vapour.

4. A method as claimed in claim 1 or 2, wherein the deactivant is dispersed
into the space from an ultra-sonic jet nebuliser.

25 5. A method as claimed in claim 3, wherein the deactivant is dispersed via a
wick dipped into a reservoir of the deactivant.

30 6. A method as claimed in any preceding claim, wherein the deactivant is
provided as a water-in-oil emulsion containing up to 2% by weight of the
deactivant.

7. A method as claimed in any of claims 1, 2 or 3, wherein the deactivant is incorporated into a candle which is burnt in the space to be treated.
8. A method as claimed in claim 7, wherein the candle comprises at least 5% by weight of the deactivant (wt of deactivant/wt of combustible body of the candle).
9. A method as claimed in claim 8, wherein the candle comprises at least 2% by weight of the deactivant (wt of deactivant/wt of combustible body of the candle).
10
10. A method as claimed in any of claims 7 to 9, wherein the candle is burnt for 2 hours or more.
11. A method as claimed in any preceding claim, wherein the deactivant is dispersed into the airspace on two or more occasions, separated by period(s) of no deactivant dispersal.
15
12. A method as claimed in any one of the preceding claims, wherein the citrus oil is orange oil.
20
13. A method as claimed in any one of the preceding claims, wherein the mint oil is spearmint oil.
14. A method as claimed in any preceding claim, and which employs as deactivant two or more of said compounds.
25
15. A method as claimed in claim 14, wherein said compounds are co-dispersed into the airspace.
16. A method as claimed in claim 14 or 15, and employing one of the following deactivant combinations:
30

- oil of bergamot and bois de rose oil;
oil of lemon grass and bois de rose oil;
a citrus oil and oil of bergamot;
5 a citrus oil and oil of jasmine.

17. Use in deactivating an allergen at a locus of one or more of the following materials:

- 10 a citrus oil;
a mint oil;
bois de rose oil;
oil of jasmine;
frankincense;
15 oil of bergamot;
oil of lemon grass.

18. Use of one or more of the following materials:

- 20 a citrus oil;
a mint oil;
bois de rose oil;
oil of jasmine;
frankincense;
25 oil of bergamot;
oil of lemon grass;

dispersed into an airspace in order to deactivate an allergen on a surface which is within that airspace.

30

19. An allergen deactivant, being one of the following:

a mixture of oil of bergamot and bois de rose oil;
a mixture of oil of lemon grass and bois de rose oil;
a mixture of a citrus oil and oil of bergamot;
a mixture of a citrus oil and oil of jasmine.

5

20. A method, use or admixed deactivant substantially as hereinbefore described with particular reference to the accompanying examples.

ABSTRACT**METHOD**

- 5 A method of deactivating an allergen comprises dispersing into an airspace containing or able to support said allergen an allergen-deactivating amount of an allergen-deactivating compound, the compound comprising one or more of the following compounds: a citrus oil; a mint oil; bois de rose oil; oil of jasmine; frankincense; oil of bergamot; and oil of lemon grass.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects/in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.